NewEdge Advisors LLC Acquires 621 Shares of VanEck Pharmaceutical ETF (NASDAQ:PPH)

NewEdge Advisors LLC raised its holdings in VanEck Pharmaceutical ETF (NASDAQ:PPH) by 8.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 8,266 shares of the company’s stock after acquiring an additional 621 shares during the period. NewEdge Advisors LLC’s holdings in VanEck Pharmaceutical ETF were worth $713,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. J.Safra Asset Management Corp boosted its stake in shares of VanEck Pharmaceutical ETF by 230.5% in the 4th quarter. J.Safra Asset Management Corp now owns 260,267 shares of the company’s stock valued at $22,391,000 after purchasing an additional 181,511 shares in the last quarter. Mivtachim The Workers Social Insurance Fund Ltd. Under Special Management lifted its stake in VanEck Pharmaceutical ETF by 117.4% in the 4th quarter. Mivtachim The Workers Social Insurance Fund Ltd. Under Special Management now owns 200,000 shares of the company’s stock valued at $17,256,000 after purchasing an additional 108,000 shares during the last quarter. Adamsbrown Wealth Consultants LLC boosted its position in VanEck Pharmaceutical ETF by 102.3% in the fourth quarter. Adamsbrown Wealth Consultants LLC now owns 149,631 shares of the company’s stock valued at $12,910,000 after buying an additional 75,659 shares in the last quarter. Independent Advisor Alliance grew its stake in shares of VanEck Pharmaceutical ETF by 19.8% during the fourth quarter. Independent Advisor Alliance now owns 58,398 shares of the company’s stock worth $5,039,000 after buying an additional 9,647 shares during the last quarter. Finally, WT Wealth Management increased its holdings in shares of VanEck Pharmaceutical ETF by 5.6% during the fourth quarter. WT Wealth Management now owns 56,690 shares of the company’s stock worth $4,891,000 after buying an additional 3,030 shares in the last quarter.

VanEck Pharmaceutical ETF Stock Performance

Shares of PPH opened at $86.79 on Friday. The stock has a market capitalization of $650.06 million, a price-to-earnings ratio of 24.60 and a beta of 0.60. VanEck Pharmaceutical ETF has a 52 week low of $77.67 and a 52 week high of $99.51. The stock has a fifty day moving average of $88.93 and a 200-day moving average of $89.07.

VanEck Pharmaceutical ETF Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, April 4th. Stockholders of record on Tuesday, April 1st were paid a dividend of $0.5245 per share. This represents a $2.10 dividend on an annualized basis and a dividend yield of 2.42%. This is a positive change from VanEck Pharmaceutical ETF’s previous quarterly dividend of $0.31. The ex-dividend date of this dividend was Tuesday, April 1st.

About VanEck Pharmaceutical ETF

The VanEck Pharmaceutical ETF (PPH) is an exchange-traded fund that is based on the MVIS US Listed Pharmaceutical 25 index, a market-cap-weighted index of 25 of the largest global pharmaceutical firms. PPH was launched on Feb 1, 2000 and is managed by VanEck.